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Abstract
Background: It is unknown whether individuals at high cardiovascular risk sustain a benefit in cardiovascular
disease from increased olive oil consumption. The aim was to assess the association between total olive oil intake,
its varieties (extra virgin and common olive oil) and the risk of cardiovascular disease and mortality in a
Mediterranean population at high cardiovascular risk.
Methods: We included 7,216 men and women at high cardiovascular risk, aged 55 to 80 years, from the
PREvención con DIeta MEDiterránea (PREDIMED) study, a multicenter, randomized, controlled, clinical trial.
Participants were randomized to one of three interventions: Mediterranean Diets supplemented with nuts or
extra-virgin olive oil, or a control low-fat diet. The present analysis was conducted as an observational prospective
cohort study. The median follow-up was 4.8 years. Cardiovascular disease (stroke, myocardial infarction and
cardiovascular death) and mortality were ascertained by medical records and National Death Index. Olive oil
consumption was evaluated with validated food frequency questionnaires. Multivariate Cox proportional hazards
and generalized estimating equations were used to assess the association between baseline and yearly repeated
measurements of olive oil intake, cardiovascular disease and mortality.
Results: During follow-up, 277 cardiovascular events and 323 deaths occurred. Participants in the highest
energy-adjusted tertile of baseline total olive oil and extra-virgin olive oil consumption had 35% (HR: 0.65; 95% CI: 0.47
to 0.89) and 39% (HR: 0.61; 95% CI: 0.44 to 0.85) cardiovascular disease risk reduction, respectively, compared to the
reference. Higher baseline total olive oil consumption was associated with 48% (HR: 0.52; 95% CI: 0.29 to 0.93) reduced
risk of cardiovascular mortality. For each 10 g/d increase in extra-virgin olive oil consumption, cardiovascular disease
and mortality risk decreased by 10% and 7%, respectively. No significant associations were found for cancer and
all-cause mortality. The associations between cardiovascular events and extra virgin olive oil intake were significant
in the Mediterranean diet intervention groups and not in the control group.
Conclusions: Olive oil consumption, specifically the extra-virgin variety, is associated with reduced risks of cardiovascular
disease and mortality in individuals at high cardiovascular risk.
Trial registration: This study was registered at controlled-trials.com (http://www.controlled-trials.com/ISRCTN35739639).
International Standard Randomized Controlled Trial Number (ISRCTN): 35739639. Registration date: 5 October 2005.
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Olive oil is a key component of the Mediterranean
Diet (MedDiet), being the main source of vegetable fat,
especially monounsaturated fatty acids (MUFA) [1]. Virgin
olive oil, produced by mechanically pressing ripe ol-
ives, contains multiple bioactive and antioxidant com-
ponents such as polyphenols, phytosterols and vitamin
E [1], and has an acidity of <1.5%. Extra-virgin olive oil
(EVOO) is also produced by mechanically pressing the
olives but is the oil with the best quality, the most in-
tense taste and its acidity is <1%. In contrast, common
olive oil, obtained from a mixture of virgin and refined oil
(usually more than 80% is refined), has fewer antioxidant
and anti-inflammatory compounds. Since refined olive oil
during the refining process loses phytochemicals, this oil
is mixed with virgin olive oil to enhance the flavor, consti-
tuting the so-called common olive oil [2].
Evidence suggests that olive oil intake is inversely as-
sociated with cardiovascular disease (CVD) in the Spanish
general population [3] and in a cohort of Italian women
[4]. In the Spanish cohort of the European Prospective
Investigation into Cancer and Nutrition (EPIC) study, total
olive oil intake has been associated with a decreased risk of
coronary heart disease, and also all-cause and cardiovas-
cular mortality [5,6]. Similarly, a lower risk of mortality
was associated with regular consumption of olive oil in
an Italian population after myocardial infarction [7] and
also in an elderly population [8]. A recent meta-analysis
concluded that epidemiologic studies consistently found
an inverse association between olive oil consumption and
stroke, but there were inconsistencies between studies
assessing coronary heart disease (CHD) as the end-point
[9]. Of note, most of the previous studies made no dis-
tinction among the different varieties of olive oil [4,7,8].
Except for the EPIC-Spanish cohort that found a greater
beneficial effect in CHD for the virgin olive oil variety
than for the common variety [5] and similar effects for
both varieties on all-cause mortality [6]. This distinction is
important because EVOO contains much higher amounts
of polyphenols than common olive oil. These polyphenols
may have cardiovascular benefits beyond the lipid profile.
It has also been reported that olive oil intake could be
beneficial in the prevention of certain cancers, such as
breast cancer [10], but the evidence is weaker.
Recently, in the context of the PREvención con DIeta
MEDiterránea (PREDIMED) Study, it has been demon-
s t r a t e dt h a taM e d D i e te n r iched with EVOO improved
lipid profile, decreased blood pressure and reduced the
risk of major cardiovascular events [11,12]. In this ob-
servational analysis of the PREDIMED population, we
aimed to assess the associations between baseline olive
oil consumption and the risk of CVD, cause-specific
and overall mortality. We hypothesized that higher con-
sumption of olive oil, especially the EVOO variety, would
be associated with a decreased risk of CVD, cause-specific
and overall mortality in an elderly Mediterranean popu-
lation at high cardiovascular risk, independent of the
allocated arm of the trial.
Methods
Study population
The present study was conducted within the framework of
the PREDIMED trial, whose design has been described
in detail elsewhere [13]. Briefly, the PREDIMED study
is a large, multicenter, parallel-group, randomized and
controlled clinical trial for the primary prevention of CVD
(http://www.predimed.es). The main results of the trial on
the primary endpoint have been published elsewhere [12].
We assigned 7,447 participants (men aged 55 to 80 years
and women 60 to 80 years) to one of three interventions:
a MedDiet supplemented with EVOO, a MedDiet supple-
mented with mixed nuts, or advice on a low-fat diet
(control diet). Participants had no CVD at enrollment, but
they were at high cardiovascular risk because of the pres-
ence of type 2 diabetes or at least three of the following risk
factors: current smoking, hypertension, high low-density
lipoprotein (LDL)-cholesterol, low high-density lipopro-
tein (HDL)-cholesterol, overweight or obesity, and family
history of premature CVD. Exclusion criteria were the
presence of any severe chronic illness, alcohol or drug
abuse, body mass index (BMI) ≥40 kg/m
2, and allergy or
intolerance to olive oil or nuts. The primary endpoint of
the main trial was a composite of cardiovascular events
(myocardial infarction, stroke or death from cardio-
vascular causes). The present analysis was conducted
as an observational prospective cohort study using
baseline consumption of olive oil as the exposure, and
taking baseline data from the date of the first visit, be-
fore the individuals were randomized to the intervention
group. The outcomes were: (a) composite of cardiovascular
events, (b) cardiovascular mortality, (c) cancer mortality
and (d) all-cause mortality. All participants provided writ-
ten informed consent according to a protocol approved by
the institutional review boards of all the recruiting centers
(Comité de Ética e Investigación Clínica [CEIC] Hospital
Universitari Sant Joan de Reus, CEIC Universidad de
Navarra, CEIC Hospital Clínic de Barcelona, Comité
de Ética Universidad de Valencia, CEIC-Parc de Salut
Mar, CEIC Hospital Universitario Araba, CEIS del distrito
Sanitario Atención Primaria Sevilla, IDIAP Jordi Gol, CEIC
Complejo Hospitalario Materno-Insular, CEIC Facultad
Medicina Universidad de Málaga, CEIC Illes Balears,
CEIC Hospital Universitari Bellvitge).
Assessment of olive oil consumption and other covariates
At baseline and yearly during the follow-up, trained
dieticians completed a 137-item semiquantitative food
frequency questionnaire (FFQ) in a face-to-face interview
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before in a population at high cardiovascular risk from
Spain. Reproducibility and validity of the FFQ for total
olive oil consumption, estimates by the Pearson correl-
ation coefficient (r) were 0.55 and 0.60, respectively, and
the intraclass correlation coefficients for reproducibility
and validity were 0.71 (P <0.001) [14]. Energy and nutrient
intake were estimated using updated Spanish food compos-
ition tables [15,16]. Information on consumption of differ-
ent types of olive oil intake was derived from the FFQ. The
questionnaire includes three different questions regarding
the consumption of olive oil: EVOO intake (produced by
mechanically pressing the olives, acidity <1%), refined olive
oil intake (refined olive oil, acidity <0.3%) and pomace olive
oil (obtained from the residue of pressing the olives and
mixed with other refined olive oils, acidity <0.3%). The die-
ticians asked the participants if they consumed one table-
spoon of olive oil (for each of the specific varieties): never,
between one to three times per month, times per week
(once, two to four, five to six, three options) or times a day
(once, two to three, four to six, more than six, four options).
These questions were transformed to continuous variables
in grams per day. The first question was used to assess
EVOO intake, the sum of the second and third questions
(refined olive oil and pomace olive oil) was considered
common olive oil intake. The sum of all the three questions
provides the total amount of olive oil consumed.
In addition, dieticians administered a validated 14-item
MedDiet screener designed to assess the degree of adher-
ence to the traditional MedDiet [17]. Two questions in the
screener are related to olive oil intake (use of olive oil as
the main fat for cooking (1 point if the answer is yes)
and using four or more tablespoons of olive oil (1 point
if the answer is yes), with 14 points the total score of the
questionnaire). To control for the overall dietary pattern,
we used this MedDiet screener removing the variables re-
lated to olive oil consumption; thus, a 12-point score was
used as a covariate in the models.
At baseline, a questionnaire about lifestyle variables,
educational achievement, history of illnesses and medica-
tion use was administered. Physical activity was assessed
using the validated Spanish version of the Minnesota
Leisure-Time Physical Activity questionnaire [18]. Partici-
pants were considered to be diabetic, hypercholesterolemic
or hypertensive if they had previously been diagnosed
as such, and/or they were being treated with antidia-
betic, cholesterol-lowering or antihypertensive agents,
respectively. Trained personnel took the anthropometric
and blood pressure measurements. Weight and height
were measured with light clothing and no shoes with
calibrated scales and a wall-mounted stadiometer, re-
spectively. Waist circumference was measured midway
between the lowest rib and the iliac crest using an an-
thropometric tape. Blood pressure was measured using
a validated oscillometer (Omron HEM705CP; Hoofddorp,
The Netherlands) in triplicate with a five-minute interval
between each measurement, and the mean of these values
was recorded.
Ascertainment of cardiovascular disease and mortality
Information on CVD and mortality was updated once a
year by the End-point Adjudication Committee, whose
members were blinded to treatment allocation and to
the dietary habits of participants. Different sources of
information were used: (a) yearly questionnaires and
examinations for all participants, (b) primary care physi-
cians, (c) yearly review of medical records, and (d) linkage
to the National Death Index. Medical records of deceased
participants were requested. The End-point Adjudication
Committee adjudicated the cause of the death and con-
firmed cardiovascular events.
Statistical analyses
Follow-up time was calculated as the interval between
the date of cardiovascular events, death (cardiovascular,
cancer or all-causes of death) or the end of follow-up
(the date of the last visit or the last recorded clinical event
of participants still alive) and the date of randomization.
Extremes of reported total energy intake (>4,000 or <800
kcal per day in men and >3,500 or <500 kcal per day in
women) were excluded from the present analysis [19].
Baseline characteristics of the studied population are pre-
sented according to energy-adjusted tertiles of total olive oil
consumption, as means (SD) for quantitative variables and
percentage (number) for categorical variables.
Multivariate Cox proportional hazard models were
used to assess the associations between baseline energy-
adjusted tertiles of olive oil intake and the risk of CVD,
cardiovascular mortality, cancer mortality and all-cause
mortality. Baseline total olive oil intake has also been
analyzed as a continuous variable. All analyses were
repeated using energy-adjusted tertiles of EVOO and
common olive oil consumption. We also tested the associa-
tions between baseline olive fruit consumption and CVD
and mortality (consumption of the whole olive fruit, not oil).
All analyses were stratified by the recruitment center.
Results are expressed as hazard ratios (HRs) with 95%
confidence intervals (CIs). Model 1 was adjusted for
age (continuous), sex and the intervention group. Model
2 was additionally adjusted for BMI (kg/m
2), smoking
status (never, former, current smoker), alcohol intake
(continuous, adding a quadratic term), educational
level (illiterate/primary education, secondary educa-
tion, academic/graduate), leisure time physical activity
(Metabolic Equivalent of Task (MET)-minutes/d), preva-
lence of diabetes (yes/no), prevalence of hypertension
(yes/no), prevalence of hypercholesterolemia (yes/no),
use of antihypertensive medication (yes/no) and use of
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baseline MedDiet adherence (12-point score). Additionally,
myocardial infarction and stroke were used as outcomes
of the analysis. Linear trend tests were assessed using the
median value to each category of total olive oil, EVOO
and common olive oil consumption and included as a
continuous variable in the various models. We used Cox
regression models to assess the association between total
olive oil and CVD, cardiovascular mortality, cancer mor-
tality and all-cause mortality separated by intervention
group. Linear trends were also tested. As a secondary
analysis and to take advantage of the updated informa-
tion of yearly intake of total olive oil, we repeated the
analysis using generalized estimating equations to assess
the association between yearly repeated measurements
of total olive oil consumption during follow-up and CVD
and mortality. For each one-year period we used as ex-
posure the average of total olive oil consumption of all
repeated measurements from baseline to the beginning
of that yearly period (between two and eight years).
Sensitivity analyses were conducted including only the
events observed in the two first years, between the second
and fourth years, and after four years of follow-up. Also,
sensitivity analyses were conducted excluding early cases
(less than one year) and late cases (more than four years).
The level of significance for all statistical tests was P<0.05
for bilateral contrast. Analyses were done using SPSS stat-
istical software, version 19 (SPSS Inc., Chicago, IL, USA).
Results
After excluding those individuals with extremes of reported
total energy intake (n = 153) and those with incomplete
baseline dietary data (n = 78), a total of 7,216 participants
were included in the present analysis. During a median of
4.8 y of follow-up we documented 277 incident cases of
major cardiovascular events, 81 cardiovascular deaths, 130
cancer deaths and 323 all-cause deaths. The mean age of
the participants was 67 y and 57.4% of them were women,
respectively. The baseline characteristics of the participants
according to energy-adjusted tertiles of total olive oil
consumption are described in Table 1. As compared
with participants in the lowest tertile of total olive oil
intake, those in the highest tertile were more likely to
have secondary education, lower total energy intake, lower
consumption of red meat and dairy products, and also to
drink less alcohol. The mean intake of total olive oil was
56.9 g/d in those participants allocated in the highest ter-
tile compared to 21.4 g/d in those of the lowest tertile.
Changes in total olive oil intake at the end of follow-up
were 3.85 ± 23.02 g/d (mean ± SD) for the combined par-
ticipants, 10.92 ± 22.91 g/d for those given MedDiet sup-
plemented with EVOO, 2.36 ± 21.81 g/d for those given
MedDiet supplemented with nuts and -3.03 ± 22.02 g/d in
the control group. The total olive oil consumption by year
during the follow-up for the total participants, and also by
the intervention group is shown in Additional file 1.
After adjusting for age, sex and intervention group,
there was a 34% (P for trend = 0.01) lower risk of major
cardiovascular events among individuals in the highest
tertile of baseline total olive oil intake as compared to those
in the reference (Table 2). The inverse association remained
statistically significant (P for trend = 0.01) after the ad-
justment for lifestyle variables and other potential con-
founders (36% lower risk (HR: 0.64; 95% CI: 0.46 to 0.87))
and even after further adjustment for MedDiet adherence
(35% lower risk (HR: 0.65; 95% CI: 0.47 to 0.89)). For each
10 g/d (one tablespoon) higher baseline total olive oil con-
sumption there was a 13% (HR: 0.87; 95% CI: 0.81 to 0.94)
decreased risk of major cardiovascular events. A 48% re-
duction in the risk of cardiovascular death (HR: 0.52; 95%
CI: 0.29 to 0.93) was found in the fully-adjusted model for
those individuals in the highest tertile of total baseline
olive oil consumption as compared to the reference. Also,
for each 10 g/d (one tablespoon) higher total baseline olive
oil consumption there was a 16% (HR: 0.84; 95% CI: 0.73
to 0.96) decreased risk of cardiovascular mortality. No
statistically significant associations were found for cancer
mortality and all-cause mortality.
The HR and 95% CIs for the association between
EVOO, CVD and also for mortality are presented in
Table 3. Baseline EVOO consumption was inversely as-
sociated with major events after adjusting for potential
confounders (39% lower risk (HR: 0.61; 95% CI: 0.44 to
0.85 (P for trend <0.01)). A non-significant inverse associ-
ation between baseline EVOO consumption and mortality
outcomes was found, specifically for overall mortality.
We observed non-significant associations between the
baseline intake of common olive oil and major events
and mortality (Table 4).
When we screened the risk of myocardial infarction and
stroke according to the different categories and varieties of
olive oil consumption it was observed that the inverse asso-
ciations were non-statistically significant (data not shown).
We have also analyzed the association between the
consumption of olive fruit (olives) and the risk of major
events. We found an association of 25% decrease in the
risk of major events in the top tertile of baseline olive
fruit consumption after adjusting for potential confounders
(HR: 0.75; 95% CI: 0.55 to 1.01, P for trend = 0.10).
The reduction in the risk of major cardiovascular events
according to tertiles of total baseline olive oil intake sepa-
rated by intervention group were 57% (HR: 0.43; 95% CI:
0.25 to 0.75, P for trend <0.01) and 55% (HR: 0.45; 95% CI:
0.25 to 0.82, P for trend <0.01) in the groups of MedDiet
supplemented with EVOO or nuts, respectively. In contrast,
the risk in the low fat control group was increased by
9% (HR: 1.09, 95% CI: 0.63 to 1.88, P for trend = 0.24)
(P-value of homogeneity test: 0.178). The association
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Baseline energy-adjusted tertiles of total olive oil consumption
Variable 1 (n = 2,405) 2 (n = 2,406) 3 (n = 2,405) P-value
Age (y) 67 ± 6 67 ± 6 67 ± 6 0.744
Men, % (n) 45.7 (1,099) 42.2 (1,016) 39.8 (956) <0.001
Intervention group, % (n) 0.476
MedDiet + EVOO 33.1 (796) 34.5 (830) 35.3 (848)
MedDiet + Nuts 32.6 (785) 32.9 (792) 32.6 (783)
Control low fat diet 34.3 (824) 32.6 (784) 32.2 (774)
BMI (kg/m
2) 29.9 ± 3.73 29.9 ± 3.88 30.0 ± 3.93 0.427
Weight (kg) 77.0 ± 11.7 76.6 ± 12.0 76.6 ± 12.1 0.422
Leisure-time energy expenditure in physical activity (MET minutes/d) 243.1 ± 265.2 228.6 ± 225.5 221.3 ± 223.1 0.005
Smoking status, % (n) 0.262
Never 60.3 (1,450) 60.9 (1,466) 63.3 (1,523)
Current 14.4 (347) 14.2 (341) 13.1 (316)
Former 25.3 (608) 24.9 (599) 23.5 (566)
Educational level, % (n) 0.040
Illiterate/primary education 79.3 (1,907) 77.6 (1,866) 76.1 (1,831)
Secondary education 14.1 (338) 14.7 (354) 16.8 (404)
Academic/graduate 6.7 (160) 7.7 (186) 7.1 (170)
Prevalence of diabetes, % (n) 49.9 (1,200) 47.9 (1,153) 48.1 (1,156) 0.312
Prevalence of hypertension, % (n) 83.1 (1,998) 82.1 (1,976) 83.0 (1,995) 0.639
Prevalence of hypercholesterolemia, % (n) 73.6 (1,769) 71.7 (1,726) 71.4 (1,716) 0.190
Family history of coronary heart disease, % (n) 22.3 (536) 22.1 (531) 22.6 (544) 0.899
Medication use, % (n)
Oral antidiabetic drugs 33.6 (808) 31.4 (756) 31.6 (759) 0.195
Antihypertensive drugs 71.9 (1,728) 72.4 (1,743) 73.9 (1,777) 0.264
Statins 40.4 (972) 40.5 (974) 39.8 (958) 0.880
Modified MedDiet score (12-point score) 6.9 ± 1.7 7.0 ± 1.7 7.2 ± 1.7 <0.001
Total energy intake (kcal/d) 2,266 ± 479 2,242 ± 668 2,199 ± 457 <0.001
Total olive oil (g/d) 21.4 ± 8.00 38.8 ± 11.6 56.9 ± 10.8 <0.001
Extra virgin olive oil (g/d) 9.1 ± 11.2 19.5 ± 20.0 34.6 ± 27.4 <0.001
Common olive oil (g/d) 12.1 ± 11.7 18.6 ± 18.5 21.7 ± 25.9 <0.001
Alcohol (g/d) 8.51 ± 14.1 9.41 ± 15.5 7.06 ± 12.2 <0.001
Nuts (g/d) 11.3 ± 14.8 10.2 ± 14.2 8.7 ± 11.5 <0.001
Vegetables (g/d) 346 ± 156 328 ± 145 327 ± 137 <0.001
Fruit (g/d) 389 ± 219 363 ± 196 351 ± 184 <0.001
Red meat (beef, pork, lamb) (g/d) 79.6 ± 49.1 79.1 ± 46.1 70.4 ± 41.2 <0.001
White meat (chicken, rabbit, turkey) (g/d) 46.4 ± 28.2 45.9 ± 27.6 42.1 ± 27.1 <0.001
Eggs (g/d) 20.5 ± 10.2 20.1 ± 11.5 19.3 ± 11.5 <0.001
Fish (g/d) 95.7 ± 51.9 99.8 ± 52.0 102 ± 46.9 <0.001
Dairy (g/d) 407 ± 231 375 ± 220 357 ± 205 <0.001
Data are expressed as means ± SD or percentage (n). P-value for comparisons across tertiles of baseline energy-adjusted olive oil consumption (Pearson chi-square test
for categorical variables or 1-way analysis of variance for continuous variable) as appropriate. BMI, body mass index; EVOO, extra virgin olive oil; MedDiet, Mediterranean
diet; MET, Metabolic Equivalent of Task.
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tive risk reductions of 41% (HR: 0.59; 95% CI: 0.32 to
1.07, P for trend = 0.050), 63% (HR: 0.37; 95% CI: 0.20
to 0.71, P for trend <0.01) and 15% (HR: 0.85; 95% CI:
0.51 to 1.41, P for trend = 0.503) in the MedDiet supple-
mented with EVOO, nuts and control group, respectively
(P-value of homogeneity test: 0.364).
The inverse association between yearly updated measure-
ments of total olive oil consumption and CVD using gener-
alized estimating equations were also statistically significant
after adjusting for potential confounders. The fully adjusted
relative risk (RR) in the highest tertile of total olive oil con-
sumption, as compared to the reference, showed a relative
risk reduction of 34% (HR: 0.66; 95% CI: 0.48 to 0.91) with
a significant linear trend test (P for trend <0.01). When we
repeated the analysis to evaluate the associations between
total olive oil consumption and cardiovascular mortality
and cancer mortality, the fully adjusted relative risk (RR)
in the top tertile of total olive oil showed a relative risk
reduction of 44% (HR: 0.56; 95% CI: 0.31 to 1.02) and 24%
(HR: 0.76; 95% CI: 0.46 to 1.24), respectively. However,
the linear trend tests were non-significant. Finally, the
fully adjusted relative risk (RR) in the top tertile of total
olive oil consumption showed a relative risk reduction of
25% (HR: 0.75; 95% CI: 0.56 to 1.00, P for trend <0.01) for
all-cause mortality.
The results of several sensitivity analyses were consistent
with the findings of the primary analysis. When only the
events observed in the first two years (91 events included)
were considered, the risk of a major event in the top
tertile of total olive oil was: 0.87 (95% CI: 0.50 to 1.51).
When only events between the second and fourth years
Table 2 Risk of cardiovascular events and mortality according to baseline total olive oil intake
Energy-adjusted tertiles of total olive oil, g/day
1 (low)
(n = 2,405)
2
(n = 2,406)
3 (high)
(n = 2,405)
P for trend Energy-adjusted
total olive oil
intake (10 g/d)
Mean total olive oil intake 21.4 ± 8.00 38.8 ± 11.6 56.9 ± 10.8
Major event
Cardiovascular event, % (n) 4.5 (108) 3.6 (86) 3.5 (83) 3.8 (277)
Multivariable model 1 1 (Ref.) 0.76 (0.57, 1.02) 0.66 (0.48, 0.90) 0.01 0.87 (0.81, 0.94)
Multivariable model 2 1 (Ref.) 0.78 (0.58, 1.04) 0.64 (0.46, 0.87) 0.01 0.87 (0.81, 0.94)
Multivariable model 3 1 (Ref.) 0.78 (0.58, 1.04) 0.65 (0.47, 0.89) 0.01 0.87 (0.81, 0.94)
Cardiovascular mortality 1 (low)
(n = 2,405)
2
(n = 2,406)
3 (high)
(n = 2,405)
P for trend
Cardiovascular mortality, % (n) 1.4 (33) 1.0 (25) 1.0 (23) 1.1 (81)
Multivariable model 1 1 (Ref.) 0.68 (0.39, 1.16) 0.52 (0.29, 0.94) 0.04 0.83 (0.72, 0.96)
Multivariable model 2 1 (Ref.) 0.70 (0.41, 1.20) 0.51 (0.28, 0.92) 0.04 0.83 (0.72, 0.95)
Multivariable model 3 1 (Ref.) 0.69 (0.40, 1.18) 0.52 (0.29, 0.93) 0.04 0.84 (0.73, 0.96)
Cancer mortality 1 (low)
(n = 2,405)
2
(n = 2,406)
3 (high)
(n = 2,405)
P for trend
Cancer mortality, % (n) 1.8 (44) 2.0 (49) 1.5 (37) 1.8 (130)
Multivariable model 1 1 (Ref.) 1.13 (0.74, 1.72) 0.80 (0.49, 1.30) 0.96 0.93 (0.83, 1.05)
Multivariable model 2 1 (Ref.) 1.13 (0.74, 1.72) 0.84 (0.52, 1.36) 0.95 0.95 (0.84, 1.07)
Multivariable model 3 1 (Ref.) 1.13 (0.74, 1.72) 0.84 (0.52, 1.37) 0.94 0.95 (0.85, 1.07)
All-cause mortality 1 (low)
(n = 2,405)
2
(n = 2,406)
3 (high)
(n = 2,405)
P for trend
All causes of mortality, % (n) 4.8 (116) 4.4 (106) 4.2 (101) 4.5 (323)
Multivariable model 1 1 (Ref.) 0.90 (0.69, 1.19) 0.79 (0.59, 1.06) 0.21 0.93 (0.87, 1.00)
Multivariable model 2 1 (Ref.) 0.90 (0.69, 1.18) 0.77 (0.58, 1.04) 0.18 0.93 (0.87, 1.00)
Multivariable model 3 1 (Ref.) 0.90 (0.69, 1.18) 0.78 (0.58, 1.05) 0.18 0.94 (0.87, 1.00)
Cox regression models were used to assess the risk of cardiovascular events and mortality by baseline energy-adjusted tertiles of total olive oil (g/day) and as a
continuous variable (10 g/d). Results were presented as Hazard Ratios (95% CI). Multivariable model 1 was adjusted for age (years), sex and theintervention group.
Model 2 was also adjusted for body mass index (BMI) (kg/m
2), smoking status (never, former, current smoker), alcohol intake (continuous, adding a quadratic
term), educational level (illiterate/primary education, secondary education, academic/graduate), leisure time physical activity (Metabolic Equivalent of Task
(MET)-minutes/d), prevalence of diabetes (yes/no), prevalence of hypertension (yes/no), prevalence of hypercholesterolemia (yes/no), use of antihypertensive
medication (yes/no) and use of statins (yes/no). Model 3 was also adjusted for Mediterranean diet adherence (Modified 12-point Mediterranean Diet score). All
models were stratified by recruitment center. Extremes of total energy intake were excluded. A major event was a composite of myocardial infarction, stroke and
death from cardiovascular causes.
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of olive oil was: 0.55 (95% CI: 0.33 to 0.93), and only
including events occurred after four years the RR was:
0.56 (95% CI: 0.31 to 1.01). The RR for the top tertile
of olive oil excluding early cases occurred in the first year
(230 events included) was 0.60 (95% CI: 0.43 to 0.85), and
excluding late cases after four years (190 events included)
the RR was 0.68 (95% CI: 0.46 to 0.98).
Discussion
In this prospective study of Mediterranean individuals at
high cardiovascular risk, we found that baseline total
olive oil consumption, especially the extra-virgin variety,
was associated with a significant reduced risk of major
cardiovascular events and cardiovascular mortality in a
Mediterranean population at high cardiovascular risk.
Relative risk reductions in CVD and all-cause mortality
were similar for the upper baseline category of total
olive oil consumption when we evaluated the repeated
measurements of total olive oil consumption over time.
We also found a reduction in cardiovascular mortality
for an increased consumption of total olive oil. Each
increase of 10 g/d in EVOO intake was associated with
a 10% reduction in the risk of cardiovascular events.
To the contrary, consumption of common olive oil was
not significantly associated with cardiovascular morbidity
and mortality.
In both MedDiet groups of our study (supplemented
either with EVOO or nuts), participants in the top tertile
of total olive oil consumption at baseline showed a lower
risk of major events compared to those in the lowest ter-
tile, but no associations were found for those individuals
Table 3 Risk of cardiovascular events and mortality according to baseline extra-virgin olive oil intake
Energy-adjusted tertiles of extra-virgin olive oil, g/day
1 (low)
(n = 2,405)
2
(n = 2,406)
3 (high)
(n = 2,405)
P for trend Energy-adjusted
extra virgin olive
oil intake (10 g/d)
Mean extra-virgin olive oil intake 9.1 ± 11.23 19.5 ± 20.0 34.6 ± 27.4
Major event
Cardiovascular event, % (n) 4.6 (111) 4.2 (101) 2.7 (65) 3.8 (277)
Multivariable model 1 1 (Ref.) 1.01 (0.77, 1.33) 0.60 (0.43, 0.82) < 0.01 0.89 (0.84, 0.95)
Multivariable model 2 1 (Ref.) 1.00 (0.76, 1.32) 0.60 (0.44, 0.84) < 0.01 0.90 (0.85, 0.95)
Multivariable model 3 1 (Ref.) 0.99 (0.75, 1.31) 0.61 (0.44, 0.85) < 0.01 0.90 (0.85, 0.95)
Cardiovascular mortality 1 (low)
(n = 2,405)
2
(n = 2,406)
3 (high)
(n = 2,405)
P for trend
Cardiovascular mortality, % (n) 1.3 (32) 1.2 (28) 0.9 (21) 1.1 (81)
Multivariable model 1 1 (Ref.) 1.01 (0.60, 1.70) 0.64 (0.36, 1.15) 0.10 0.93 (0.84, 1.03)
Multivariable model 2 1 (Ref.) 0.99 (0.59, 1.67) 0.64 (0.36, 1.15) 0.10 0.93 (0.83, 1.03)
Multivariable model 3 1 (Ref.) 0.97 (0.58, 1.64) 0.65 (0.36, 1.17) 0.13 0.93 (0.84, 1.03)
Cancer mortality 1 (low)
(n = 2,405)
2
(n = 2,406)
3 (high)
(n = 2,405)
P for trend
Cancer mortality, % (n) 2.1 (50) 1.7 (41) 1.6 (39) 1.8 (130)
Multivariable model 1 1 (Ref.) 0.90 (0.59, 1.37) 0.87 (0.56, 1.37) 0.61 0.96 (0.88, 1.04)
Multivariable model 2 1 (Ref.) 0.88 (0.58, 1.35) 0.88 (0.56, 1.39) 0.68 0.96 (0.89, 1.05)
Multivariable model 3 1 (Ref.) 0.89 (0.58, 1.35) 0.90 (0.57, 1.41) 0.73 0.97 (0.89, 1.05)
All-cause mortality 1 (low)
(n = 2,405)
2
(n = 2,406)
3 (high)
(n = 2,405)
P for trend
All causes of mortality, % (n) 5.2 (125) 4.2 (100) 4.1 (98) 4.5 (323)
Multivariable model 1 1 (Ref.) 0.88 (0.67, 1.15) 0.81 (0.61, 1.07) 0.19 0.95 (0.91, 1.00)
Multivariable model 2 1 (Ref.) 0.84 (0.64, 1.10) 0.80 (0.60, 1.07) 0.20 0.95 (0.90, 1.00)
Multivariable model 3 1 (Ref.) 0.84 (0.64, 1.10) 0.82 (0.61, 1.09) 0.25 0.96 (0.91, 1.01)
Cox regression models were used to assess the risk of cardiovascular events and mortality by baseline energy-adjusted tertiles of extra virgin olive oil (g/day) and as a
continuous variable (10 g/d). Results were presented as Hazard Ratios (95% CI). Multivariable model 1 was adjusted for age (years), sex and the intervention group.
Model 2 was also adjusted for body mass index (BMI) (kg/m
2), smoking status (never, former, current smoker), alcohol intake (continuous, adding a quadratic term),
educational level (illiterate/primary education, secondary education, academic/graduate), leisure time physical activity (Metabolic Equivalent of Task (MET)-minutes/d),
prevalence of diabetes (yes/no), prevalence of hypertension (yes/no), prevalence of hypercholesterolemia (yes/no), use of antihypertensive medication (yes/no) and use
of statins (yes/no). Model 3 was also adjusted for Mediterranean diet adherence (Modified 12-point Mediterranean Diet score). All models were stratified by recruitment
center. Extremes of total energy intake were excluded. A major event was a composite of myocardial infarction, stroke and death from cardiovascular causes.
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http://www.biomedcentral.com/1741-7015/12/78allocated to the control group. One explanation could be
that the advice against eating fat food such as olive oil in
the low fat control group throughout the study might
have counterbalanced the protective effect of a lifetime
intake of olive oil. However, we found inverse associa-
tions between olive oil consumption and CVD not only
in the group supplemented with EVOO but also in the
nuts group. Although it is difficult to isolate the effect
of a single food because a range of foods are consumed
in the whole diet, our study was able to distinguish the
effects attributed to olive oil, a food that it is clearly a key
component of the MedDiet. The positive association found
in the MedDiet groups seems to confirm these effects.
Recent findings of the PREDIMED Study have dem-
onstrated that adherence to the Mediterranean dietary
pattern, as a whole and enriched with EVOO or nuts,
reduce the incidence of major cardiovascular events by
30% within the context of primary prevention [12]. Our re-
sults further confirm the important role that olive oil con-
sumption may play, even though other key components of
the MedDiet, such as nuts, vegetables, fruits, legumes,
fish and wine could also contribute to the observed
beneficial effects. In agreement with our results, previ-
ous observational studies found an inverse association
between olive oil consumption and CVD. Thus, in the
EPICOR study conducted in 30,000 Italian women
followed for 7.8 years, a 44% reduction in the risk of
CHD was observed in those women in the top quartile of
total olive oil consumption compared to those in the lo-
west quartile [4]. Similarly, the hazard ratio of CHD in
Table 4 Risk of cardiovascular events and mortality according to baseline common olive oil intake
Energy-adjusted tertiles of common olive oil, g/day
1 (low)
(n = 2,405)
2
(n = 2,406)
3 (high)
(n = 2,405)
P for trend Energy-adjusted
common olive oil
intake (10 g/d)
Mean common olive oil intake 12.1 ± 11.7 18.6 ± 18.5 21.7 ± 25.9
Major event
Cardiovascular event, % (n) 3.5 (85) 3.6 (86) 4.4 (106) 3.8 (277)
Multivariable model 1 1 (Ref.) 1.06 (0.78, 1.45) 1.20 (0.88, 1.62) 0.23 1.04 (0.99, 1.10)
Multivariable model 2 1 (Ref.) 1.01 (0.74, 1.38) 1.13 (0.83, 1.54) 0.35 1.04 (0.98, 1.10)
Multivariable model 3 1 (Ref.) 0.99 (0.73, 1.36) 1.11 (0.82, 1.51) 0.40 1.03 (0.98, 1.09)
Cardiovascular mortality 1 (low)
(n = 2,405)
2
(n = 2,406)
3 (high)
(n = 2,405)
P for trend
Cardiovascular mortality, % (n) 1.3 (31) 1.0 (24) 1.1 (26) 1.1 (81)
Multivariable model 1 1 (Ref.) 0.87 (0.50, 1.51) 0.84 (0.48, 1.46) 0.60 0.98 (0.88, 1.09)
Multivariable model 2 1 (Ref.) 0.84 (0.48, 1.47) 0.84 (0.48, 1.48) 0.65 0.98 (0.88, 1.09)
Multivariable model 3 1 (Ref.) 0.83 (0.47, 1.46) 0.81 (0.46, 1.43) 0.56 0.98 (0.87, 1.09)
Cancer mortality 1 (low)
(n = 2,405)
2
(n = 2,406)
3 (high)
(n = 2,405)
P for trend
Cancer mortality, % (n) 1.7 (40) 1.7 (42) 2.0 (48) 1.8 (130)
Multivariable model 1 1 (Ref.) 1.07 (0.68, 1.68) 1.16 (0.74, 1.82) 0.51 1.01 (0.92, 1.10)
Multivariable model 2 1 (Ref.) 1.04 (0.66, 1.64) 1.16 (0.74, 1.82) 0.49 1.01 (0.93, 1.10)
Multivariable model 3 1 (Ref.) 1.03 (0.65, 1.62) 1.14 (0.73, 1.79) 0.52 1.01 (0.92, 1.10)
All-cause mortality 1 (low)
(n = 2,405)
2
(n = 2,406)
3 (high)
(n = 2,405)
P for trend
All causes of mortality, % (n) 4.2 (101) 4.4 (106) 4.8 (116) 4.5 (323)
Multivariable model 1 1 (Ref.) 1.14 (0.86, 1.51) 1.17 (0.88, 1.51) 0.34 1.01 (0.96, 1.07)
Multivariable model 2 1 (Ref.) 1.10 (0.83, 1.47) 1.16 (0.87, 1.54) 0.37 1.01 (0.96, 1.07)
Multivariable model 3 1 (Ref.) 1.09 (0.82, 1.45) 1.14 (0.85, 1.51) 0.44 1.01 (0.96, 1.07)
Cox regression models were used to assess the risk of cardiovascular events and mortality by baseline energy-adjusted tertiles of common olive oil (g/day) and as
a continuous variable (10 g/d). Results were presented as Hazard Ratios (95% CI). Multivariable model 1 was adjusted for age (years), sex and the intervention group.
Model 2 was also adjusted for body mass index (BMI) (kg/m
2), smoking status (never, former, current smoker), alcohol intake (continuous, adding a quadratic term),
educational level (illiterate/primary education, secondary education, academic/graduate), leisure time physical activity (Metabolic Equivalent of Task (MET)-minutes/d),
prevalence of diabetes (yes/no), prevalence of hypertension (yes/no), prevalence of hypercholesterolemia (yes/no), use of antihypertensive medication (yes/no) and use
of statins (yes/no). Model 3 was also adjusted for Mediterranean diet adherence (Modified 12-point Mediterranean Diet score). All models were stratified by recruitment
center. Extremes of total energy intake were excluded. A major event was a composite of myocardial infarction, stroke and death from cardiovascular causes.
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the Spanish EPIC cohort was 0.78 (95% CI: 0.59 to 1.03)
compared to the reference, after a 10.4-year follow-up. In
this study, the reduction of CHD risk was greater for vir-
gin olive oil than for the common variety [5].
We found a strong relationship between total olive oil
consumption and the composite of cardiovascular major
events, but when we analyzed separately myocardial in-
farction and stroke, the associations were non-significant.
This could be explained by the lack of statistical power,
but, according to our results, two previous case-control
studies conducted in an Italian population also reported
no associations between olive oil intake and myocardial
infarction [20,21].
Our data suggest that total olive oil intake was in-
versely associated with cardiovascular mortality but not
with cancer mortality: each 10 g/d increase in total olive
oil consumption is associated with a 16% reduction in
cardiovascular mortality. These results are supported by
the findings of EPIC-Spain, where a 44% reduction in
CVD mortality was found in participants at the top quartile
of total olive oil consumption compared to those in the
bottom quartile [6] and they can contribute to solving
the inconsistencies reported by a recent meta-analysis [9].
In the same study of EPIC-Spain, total olive oil intake was
not associated with cancer mortality [6]. However, like our
study, this study did not examine specific types of cancer.
A recent review of epidemiological studies reported some
evidence suggesting that olive oil can decrease the risk of
upper digestive and respiratory tract neoplasms, breast
cancer and probably cancer in other sites [10]. Therefore,
future larger studies or meta-analyses may need to focus
on incidence and mortality of specific cancer sites.
The outcomes regarding olive oil consumption and
all-cause mortality have been inconsistent, as reported in
a recent meta-analysis including a large number of partici-
pants [9]. A previous study conducted in participants from
Italy, who have suffered a myocardial infarction, showed that
there was a 24% (HR: 0.76; 95% CI: 0.64 to 0.91) reduction
in the risk of overall mortality for those consuming olive
oil regularly compared to those who never consumed
olive oil [7]. The results from the EPIC-cohort indicated
a 26% (HR: 0.74; 95% CI: 0.64 to 0.87) reduction in the
risk of overall mortality for those in the highest quartile
of total olive oil intake compared to the lowest quartile
[6]. On the contrary, no associations were found between
total olive oil intake and all-cause mortality in a free-
living Greek population [22]. Our findings suggest a
non-significant possible inverse relation between each
10 g/d (one tablespoon of oil) increase in total olive oil
and EVOO consumption and all-cause mortality.
The inverse associations between olive oil consumption
and CVD could be explained by several mechanisms.
T h eb e n e f i c i a le f f e c t so fo l i v eo i la r em a i n l ya t t r i b u t e d
to its high content on MUFAs (that are less susceptible to
oxidation than other type of fatty acids) but also to other
minor components with important biological properties,
such as phenolic compounds, vitamin E and other lipid-
derivate molecules (squalene, tocopherols, triterpenic
alcohols and so on), especially occurring in EVOO [2,3].
Evidence suggests that olive oil has anti-inflammatory
and anti-atherogenic effects and it may also play a beneficial
role in reducing oxidative stress and improving endothelial
function [3,23,24]. Moreover, it has been observed that
EVOO, particularly in a context of a MedDiet, improved
lipid profile, insulin sensitivity, glycemic control, decreased
blood pressure [11,24-27] and also was inversely associated
with new-onset diabetes [28], all of them considered strong
risk factors for CVD.
The strengths of the present study are its prospective
design and a relatively long duration of follow-up. In
addition, previous studies made no distinctions among
different varieties of olive oil, but we analyzed the associa-
tions for EVOO and common olive oil separately. The
present study was conducted in a population where the
intake of total olive oil was relatively high, allowing a
better assessment of the association between olive oil
consumption and CVD or mortality.
Some limitations of our study deserve attention. First,
the generalizability of our results may be limited, as the
studied population was composed of Mediterranean elderly
individuals at high cardiovascular risk who increased their
intake of olive oil due to the intervention. However, the
findings from our study are broadly consistent with those
from other populations. Although the individuals changed
their oil consumption during the study and this could have
affected the observed beneficial effects of olive oil, it should
be noted that the baseline intake of olive oil was high
and the baseline assessment can be considered as a good
correlate of lifetime habits in this population. Second,
because of the observational nature of the study, residual
confounding remains a possibility even though our analyses
were extensively adjusted for a wide range of cardiovascu-
lar risk factors. Nonetheless, our observational findings
are consistent with the intervention effects observed in
the olive oil enriched arm in the PREDIMED trial. Finally,
although the FFQ used was validated, measurement errors
are inevitable, especially regarding self-reported different
varieties of olive oil.
Conclusions
In summary, we found that greater consumption of total
olive oil, especially EVOO, was associated with reduced
cardiovascular disease and mortality risk in an elderly
Mediterranean population at high cardiovascular risk.
Our findings underscore olive oil consumption as one
of the key components of the MedDiet for cardiovascu-
lar disease prevention.
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